secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0001193125-22-250665
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharmaceuticals appoints James Topper, M.D., Ph.D. to Board of Directors
--------------------------------------------------------------------------------

- James Topper appointed as Class III director effective September 22, 2022; will serve on nominating and corporate governance committee.
- Topper previously served on board from January 2018 to May 2021; currently Managing General Partner at Frazier Life Sciences.
- Granted option to purchase 20,000 shares vesting over three years; cash compensation per Non-Employee Director Compensation Program.
- Board determined Topper meets Nasdaq independence requirements; no related person transactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522250665/0001193125-22-250665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312522250665/d361727d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-250665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer